519 related articles for article (PubMed ID: 9445202)
1. Mono-L-aspartyl chlorin e6 (NPe6) and hematoporphyrin derivative (HpD) in photodynamic therapy administered to a human cholangiocarcinoma model.
Wong Kee Song LM; Wang KK; Zinsmeister AR
Cancer; 1998 Jan; 82(2):421-7. PubMed ID: 9445202
[TBL] [Abstract][Full Text] [Related]
2. Photodynamic therapy using mono-L-aspartyl chlorin e6 (Npe6) for the treatment of cutaneous disease: a Phase I clinical study.
Taber SW; Fingar VH; Coots CT; Wieman TJ
Clin Cancer Res; 1998 Nov; 4(11):2741-6. PubMed ID: 9829737
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and clinical effects of mono-L-aspartyl chlorin e6 (NPe6) photodynamic therapy in adult patients with primary or secondary cancer of the skin and mucosal surfaces.
Chan AL; Juarez M; Allen R; Volz W; Albertson T
Photodermatol Photoimmunol Photomed; 2005 Apr; 21(2):72-8. PubMed ID: 15752124
[TBL] [Abstract][Full Text] [Related]
4. Photodynamic therapy of intestinal tumors with mono-L-aspartyl chlorin e6 (NPe6): a basic study.
Kikuchi T; Asakura T; Aihara H; Shiraki M; Takagi S; Kinouchi Y; Aizawa K; Shimosegawa T
Anticancer Res; 2003; 23(6C):4897-900. PubMed ID: 14981942
[TBL] [Abstract][Full Text] [Related]
5. Photodynamic therapy with mono-L-aspartyl chlorin e6 can cause necrosis of squamous cell carcinoma of tongue: experimental study on an animal model of nude mouse.
Kobayashi W; Liu Q; Nakagawa H; Sakaki H; Teh B; Matsumiya T; Yoshida H; Imaizumi T; Satoh K; Kimura H
Oral Oncol; 2006 Jan; 42(1):46-50. PubMed ID: 16266818
[TBL] [Abstract][Full Text] [Related]
6. In vivo studies on the utilization of mono-L-aspartyl chlorin (NPe6) for photodynamic therapy.
Nelson JS; Roberts WG; Berns MW
Cancer Res; 1987 Sep; 47(17):4681-5. PubMed ID: 2957047
[TBL] [Abstract][Full Text] [Related]
7. Tissue distribution and photosensitizing properties of mono-L-aspartyl chlorin e6 in a mouse tumor model.
Gomer CJ; Ferrario A
Cancer Res; 1990 Jul; 50(13):3985-90. PubMed ID: 2354446
[TBL] [Abstract][Full Text] [Related]
8. Effects of photodynamic therapy using a fractionated dosing of mono-L-aspartyl chlorin e6 in a murine tumor.
Webber J; Leeson B; Fromm D; Kessel D
J Photochem Photobiol B; 2005 Feb; 78(2):135-40. PubMed ID: 15664500
[TBL] [Abstract][Full Text] [Related]
9. Metabolic properties and photosensitizing responsiveness of mono-L-aspartyl chlorin e6 in a mouse tumor model.
Ferrario A; Kessel D; Gomer CJ
Cancer Res; 1992 May; 52(10):2890-3. PubMed ID: 1581904
[TBL] [Abstract][Full Text] [Related]
10. Effects of photodynamic therapy using mono-L-aspartyl chlorin e6 on vessel constriction, vessel leakage, and tumor response.
McMahon KS; Wieman TJ; Moore PH; Fingar VH
Cancer Res; 1994 Oct; 54(20):5374-9. PubMed ID: 7923168
[TBL] [Abstract][Full Text] [Related]
11. Endovascular photodynamic therapy using mono-L-aspartyl-chlorin e6 to inhibit Intimal hyperplasia in balloon-injured rabbit arteries.
Nagae T; Aizawa K; Uchimura N; Tani D; Abe M; Fujishima K; Wilson SE; Ishimaru S
Lasers Surg Med; 2001; 28(4):381-8. PubMed ID: 11344521
[TBL] [Abstract][Full Text] [Related]
12. [Hematoporphyrin derivative-mediated photodynamic therapy for human nasopharyngeal carcinoma: a comparative study with CNE2 and C666-1 cell lines in vitro].
Yang XM; Luo RC; Ma HJ; Li LB; Ding XM; Yan X; Lü CW; Zhou XP
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Feb; 27(2):165-7. PubMed ID: 17355926
[TBL] [Abstract][Full Text] [Related]
13. [Photodynamic therapy of hematoporphyrin derivative on human pancreatic carcinoma cell lines].
Zhao Y; Yang B; Zhang T; Cai L; Zhu Y
Zhonghua Wai Ke Za Zhi; 2000 Mar; 38(3):204-7. PubMed ID: 11832030
[TBL] [Abstract][Full Text] [Related]
14. A photodynamic therapy combined with topical 5-aminolevulinic acid and systemic hematoporphyrin derivative is more efficient but less phototoxic for cancer.
Wang Y; Lin Y; Zhang HG; Zhu J
J Cancer Res Clin Oncol; 2016 Apr; 142(4):813-21. PubMed ID: 26581214
[TBL] [Abstract][Full Text] [Related]
15. A comparative study of 28 porphyrins and their abilities to localize in mammary mouse carcinoma: uroporphyrin I superior to hematoporphyrin derivative.
El-Far M; Pimstone N
Prog Clin Biol Res; 1984; 170():661-72. PubMed ID: 6241706
[TBL] [Abstract][Full Text] [Related]
16. Photodynamic effect in an experimental bladder tumor treated with intratumor injection of hematoporphyrin derivative.
Lin CW; Amano T; Rutledge AR; Shulok JR; Prout GR
Cancer Res; 1988 Nov; 48(21):6115-20. PubMed ID: 2971434
[TBL] [Abstract][Full Text] [Related]
17. Active oxygen intermediates in the degradation of hematoporphyrin derivative in tumor cells subjected to photodynamic therapy.
Chekulayeva LV; Chekulayev VA; Shevchuk IN
J Photochem Photobiol B; 2008 Nov; 93(2):94-107. PubMed ID: 18760622
[TBL] [Abstract][Full Text] [Related]
18. [A basic study of photodynamic therapy of experimental hepatoma with ME 2906].
Nakamura J; Kajiwara H; Nakamura M; Watanabe M; Naganuma K; Tanaka H; Usui S; Sumiyama Y; Saito K; Aizawa K
Gan To Kagaku Ryoho; 1998 Jul; 25(9):1454-6. PubMed ID: 9703852
[TBL] [Abstract][Full Text] [Related]
19. The effects of serum on cellular uptake and phototoxicity of mono-L-aspartyl chlorin e6 (NPe6) in vitro.
Sheyhedin I; Aizawa K; Araake M; Kumasaka H; Okunaka T; Kato H
Photochem Photobiol; 1998 Jul; 68(1):110-4. PubMed ID: 9679456
[TBL] [Abstract][Full Text] [Related]
20. Influence of temperature on the efficiency of photodestruction of Ehrlich ascites carcinoma cells sensitized by hematoporphyrin derivative.
Chekulayeva LV; Shevchuk IN; Chekulayev VA
Exp Oncol; 2004 Jun; 26(2):125-39. PubMed ID: 15273663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
